AstraZeneca

MedImmune, is a company that produces Synagis, a drug for the prevention of respiratory infections in infants, which accounted for US$ 1.06 billion of its US$ 1.2 billion in revenue for 2005, and FluMist, a nasal spray influenza vaccine introduced in 2004. MedImmune has over 120 drugs in development for conditions including lupus, COPD, asthma, and many types of cancer.

MedImmune

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

A small-scale study of AstraZeneca Plc (NASDAQ: AZN) COVID-19 combined with Sputnik Light vaccines has shown robust antibody growth in most of the study's participants, citing the Russian Direct Investment Fund Reuters reported. The data was collected from 20 people who took part in a 100-person study in Azerbaijan in February.

AstraZeneca, Sputnik Light COVID-19 Vaccine Mix Shows Strong Antibody Growth: Reuters

Merck

AstraZeneca (AZN) and Merck (MRK) announce that their PARP inhibitor Lynparza succeeds in meeting the primary endpoint in a late-stage study, evaluating it in first-line castration-resistant prostate cancer patients.

AstraZeneca, Merck's Lynparza Prostate Cancer Study Meets Goal

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca will present data across its COVID-19 and respiratory syncytial virus (RSV) pipeline at the 10th Annual IDWeek Virtual Conference, September 29 to October 3, 2021, illustrating its commitment to advancing innovative science in infectious diseases. Data featuring AstraZeneca's investigational long-acting antibody (LAAB) programs – AZD7442 for COVID-19 and nirsevimab for RSV – as well as AZD1222, will be presented as three late-breaking oral presenta

AstraZeneca COVID-19 and RSV presentations at IDWeek 2021 will showcase scientific progress in infectious diseases

AstraZeneca (AZN) inks a deal to gain the rights to the self-amplifying RNA platform developed by the Imperial College London.

AstraZeneca (AZN) Inks Deal to Enter Novel RNA Therapeutic Space

AstraZeneca plc seems to be moving on from the COVID-19 vaccine focus as its oncology pipeline keeps delivering strong results, while it's entering new areas of research with Alexion and Imperial College London. On Friday, its Lynparza candidate showed better results when used with the current standard of care, called abiterone, than abiterone alone in patients with castration-resistant prostate cancer.

Is AstraZeneca ready to leave COVID-19 vaccines behind?

AstraZeneca Plc (NASDAQ: AZN) has reported high-level results from the PROpel Phase 3 trial of Lynparza (olaparib) in metastatic castration-resistant prostate cancer (mCRPC). The data showed Lynparza plus abiraterone demonstrated improvement in radiographic progression-free survival (rPFS) versus abiraterone as a 1st-line treatment for mCRPC with or without homologous recombination repair (HRR) gene mutations.

AstraZeneca - Merck's Lynparza Delays Disease Progression In Prostate Cancer Patients

AstraZeneca PLC announced that its Lynparza candidate in combination with abiraterone helped patients with prostate cancer in a late-stage clinical trial. It was used in men with metastatic tumours that are castration-resistant (mCRPC), with or without a certain type of gene mutations called homologous recombination repair (HRR).

AstraZeneca posts positive results for prostate cancer candidate

British American Tobacco

Altria

Walmart

With markets jittery due to a potential crisis in China, here are four low beta stocks to buy for portfolio protection and dividends. The post 4 Stocks to Buy for Protection From an Evergrande-Driven Correction appeared first on InvestorPlace.

4 Stocks to Buy for Protection From an Evergrande-Driven Correction

AstraZeneca Plc (NASDAQ: AZN) struck a deal with a startup for a self-amplifying RNA (saRNA) therapeutics platform developed at Imperial College London. Under the deal, VaxEquity could receive up to $195 million in milestones payments, in addition to royalties on approved drugs.

AstraZeneca Invests In Imperial College's Self-Amplifying RNA Tech

AstraZeneca AZN, -0.66% AZN, +0.86% has teamed up with a startup from Imperial College London to expand disease fighting beyond COVID-19 using next generation messenger RNA technology. That's according to the professor leading Imperial's research, Robin Shattock, who made the comments in an interview with Bloomberg that published on Thursday.

AstraZeneca, Imperial College to partner on RNA technology: report

AstraZeneca Plc on Thursday struck a deal with the firm behind Imperial College London's experimental COVID-19 vaccine to develop and sell drugs based on its self-amplifying RNA technology platform in other disease areas.

AstraZeneca invests in Imperial's self-amplifying RNA technology with eye on future drugs

AstraZeneca's (AZN) Enhertu reduces the risk of disease progression by 72% in HER2-positive metastatic breast cancer. Imfinzi plus chemotherapy triples patient survival at three years in ES-SCLC.

AstraZeneca (AZN) Up on Enhertu, Imfinzi Cancer Data at ESMO

AstraZeneca plc (NASDAQ: AZN) will invest $360 million to develop a manufacturing facility in Ireland to produce active pharmaceutical ingredients (APIs). The planned investment at the Alexion Campus in College Park, Dublin, is expected to create about 100 highly skilled direct jobs.

AstraZeneca To Inject $360M In Irish API Manufacturing Site

The company's next-generation treatment for breast cancer could become the new standard of care.

Here's Why Everyone's Talking About AstraZeneca Right Now

AstraZeneca PLC plans to invest US$360mln in a new ingredients plant in Ireland that is expected transform the development and commercialisation of new medicines. In a statement, the pharmaceuticals group said the next-generation active pharmaceutical ingredient (API) manufacturing facility for small molecules, which will be located at the Alexion Campus in College Park in Dublin, will support its global supply network and make it fit for future growth.

AstraZeneca to invest US$360mln in manufacturing plant in Ireland

(Reuters) -AstraZeneca said on Tuesday it would invest $360 million to develop a manufacturing facility in Ireland to produce active pharmaceutical ingredients (APIs), or the main components of medicines.

AstraZeneca to invest $360 million in Irish drug manufacturing site

AstraZeneca PLC (AZN) Presents at ESMO Investor Science Broker Conference - (Transcript)

If all AstraZeneca did in the last year was team with Oxford University in a heroic quest to design, test, and deliver in record time one of the.

Breakthrough AstraZeneca Breast Cancer Drug Massively Reduces Disease and Fatalities in Trial

Surface Oncology Inc

The pharmaceutical giant reports encouraging results from a late-stage ES-SCLC trial of blockbuster cancer treatment Imfinzi.

Why AstraZeneca and Surface Oncology Rose Today

AstraZeneca Plc (NASDAQ: AZN) and Daiichi Sankyo's (OTC: DSNKY) Enhertu have shown some striking data in late-stage breast cancer trials and early solid tumor tests.  What Happened: The Phase 3 DESTINY-Breast03 head-to-head study included second-line unresectable or metastatic HER2-positive breast cancer patients who had previously undergone treatment with a Herceptin-chemo combo.

AstraZeneca's Enhertu Posts Substantial Clinical Benefit Over Roche's Kadcyla In Breast Cancer Trials

AstraZeneca PLC (NASDAQ: AZN) is trading higher Monday after the company announced its Enhertu data that was presented at the European Society for Medical Oncology showed reduced risk of disease progression by 72% in patients with HER2-Positive metastatic breast cancer. There was a strong trend towards improved overall survival, however this analysis is not yet mature and is not statistically significant.

Why AstraZeneca Shares Are Trading Higher Today

AstraZeneca plc (NASDAQ: AZN) announced updated data from the CASPIAN Phase 3 trial of Imfinzi (durvalumab) combined with a choice of chemotherapies etoposide plus either carboplatin or cisplatin. The Imfinzi-chemotherapy demonstrated a sustained, clinically meaningful overall survival (OS) benefit at three years for adults with extensive-stage small cell lung cancer (ES-SCLC) treated in the 1st-line setting.

AstraZeneca Touts Longest Survival Update In Lung Cancer Setting With Imfinzi/Chemo Data

AstraZeneca said interim analysis of a Phase 3 trial showed that its drug Enhertu reduced the risk of death or disease progression by 72% compared with an existing treatment.

AstraZeneca Stock Climbs on ‘Groundbreaking' Breast Cancer Drug Trial Results

More than £2bn was added to the value of AstraZeneca PLC after it reported “ground-breaking” results from a trial of its breast cancer drug Enhertu. The phase III evaluation compared the AZ treatment's performance against the standard of care for HER2-positive metastatic breast cancer, the European Society of Medical Oncology (ESMO) annual conference was told.

AstraZeneca PLC: £2bn added to the value after "ground-breaking" breast cancer trial results. But just how much higher will its shares go?

Daiichi Sankyo Co Ltd

AstraZeneca Plc (NASDAQ: AZN) and Daiichi Sankyo (OTC: DSNKY) announced detailed results from the positive DESTINY-Gastric02 Phase 2 trial of Enhertu (fam-trastuzumab deruxtecan-nxki). The trial included HER2-positive metastatic and/or unresectable gastric or gastroesophageal junction (GEJ) adenocarcinoma patients previously treated with a trastuzumab-containing regimen.

News for AstraZeneca Stock (AZN)